Consensus 3c. Raises FY24 revenue view to $835M-$845M from $820M-$840M, consensus $831.73M. Raises FY24 adjusted EBITDA view to $25M-$35M from $20M-$30M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
- Myriad Genetics appoints Jennifer Fox as CLO
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics announces results from nationwide Cancer Risk Survey
- What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk